167 related articles for article (PubMed ID: 37090516)
1. Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development.
Nameki RA; Chang H; Yu P; Abbasi F; Lin X; Reddy J; Haro M; Fonseca MA; Freedman ML; Drapkin R; Corona RI; Lawrenson K
bioRxiv; 2023 Apr; ():. PubMed ID: 37090516
[TBL] [Abstract][Full Text] [Related]
2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
3. Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.
Elias KM; Emori MM; Westerling T; Long H; Budina-Kolomets A; Li F; MacDuffie E; Davis MR; Holman A; Lawney B; Freedman ML; Quackenbush J; Brown M; Drapkin R
JCI Insight; 2016 Aug; 1(13):. PubMed ID: 27617304
[TBL] [Abstract][Full Text] [Related]
4. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
[TBL] [Abstract][Full Text] [Related]
5. Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.
de Cristofaro T; Di Palma T; Soriano AA; Monticelli A; Affinito O; Cocozza S; Zannini M
Oncotarget; 2016 Jul; 7(27):41929-41947. PubMed ID: 27259239
[TBL] [Abstract][Full Text] [Related]
6. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.
Rodgers LH; Ó hAinmhire E; Young AN; Burdette JE
Oncotarget; 2016 May; 7(22):32785-95. PubMed ID: 27129161
[TBL] [Abstract][Full Text] [Related]
7. The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.
Chaves-Moreira D; Mitchell MA; Arruza C; Rawat P; Sidoli S; Nameki R; Reddy J; Corona RI; Afeyan LK; Klein IA; Ma S; Winterhoff B; Konecny GE; Garcia BA; Brady DC; Lawrenson K; Morin PJ; Drapkin R
Sci Signal; 2022 Apr; 15(728):eabm2496. PubMed ID: 35380877
[TBL] [Abstract][Full Text] [Related]
8. Cell Origins of High-Grade Serous Ovarian Cancer.
Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
[TBL] [Abstract][Full Text] [Related]
9. UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer.
Hardy LR; Salvi A; Burdette JE
Cancers (Basel); 2018 Aug; 10(8):. PubMed ID: 30096791
[TBL] [Abstract][Full Text] [Related]
10. SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
Lin L; Shi K; Zhou S; Cai MC; Zhang C; Sun Y; Zang J; Cheng L; Ye K; Ma P; Shen P; Zhang M; Cheng Y; Qi C; Li Y; Yin X; Zheng Y; Tan L; Zhuang G; Zang R
Oncogene; 2022 Mar; 41(12):1767-1779. PubMed ID: 35124696
[TBL] [Abstract][Full Text] [Related]
11. PAX8 modulates the tumor microenvironment of high grade serous ovarian cancer through changes in the secretome.
Salvi A; Hardy LR; Heath KN; Watry S; Pergande MR; Cologna SM; Burdette JE
Neoplasia; 2023 Feb; 36():100866. PubMed ID: 36586182
[TBL] [Abstract][Full Text] [Related]
12. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP
J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522
[TBL] [Abstract][Full Text] [Related]
13. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.
Lawrenson K; Fonseca MAS; Liu AY; Segato Dezem F; Lee JM; Lin X; Corona RI; Abbasi F; Vavra KC; Dinh HQ; Gill NK; Seo JH; Coetzee S; Lin YG; Pejovic T; Mhawech-Fauceglia P; Rowat AC; Drapkin R; Karlan BY; Hazelett DJ; Freedman ML; Gayther SA; Noushmehr H
Cell Rep; 2019 Dec; 29(11):3726-3735.e4. PubMed ID: 31825847
[TBL] [Abstract][Full Text] [Related]
14. PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far.
Di Palma T; Zannini M
Onco Targets Ther; 2022; 15():1273-1280. PubMed ID: 36275185
[TBL] [Abstract][Full Text] [Related]
15. Tubal origin of 'ovarian' low-grade serous carcinoma.
Li J; Abushahin N; Pang S; Xiang L; Chambers SK; Fadare O; Kong B; Zheng W
Mod Pathol; 2011 Nov; 24(11):1488-99. PubMed ID: 21701538
[TBL] [Abstract][Full Text] [Related]
16. PAX8, an Emerging Player in Ovarian Cancer.
Gokulnath P; Soriano AA; de Cristofaro T; Di Palma T; Zannini M
Adv Exp Med Biol; 2021; 1330():95-112. PubMed ID: 34339032
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
[TBL] [Abstract][Full Text] [Related]
18. YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.
Hua G; Lv X; He C; Remmenga SW; Rodabough KJ; Dong J; Yang L; Lele SM; Yang P; Zhou J; Karst A; Drapkin RI; Davis JS; Wang C
Oncogene; 2016 Apr; 35(17):2247-65. PubMed ID: 26364602
[TBL] [Abstract][Full Text] [Related]
19. High-Grade Serous Carcinoma Involving Fallopian Tube, Ovary and Peritoneum.
Al-Agha OM; Blake Gilks C
Surg Pathol Clin; 2011 Mar; 4(1):375-96. PubMed ID: 26837299
[TBL] [Abstract][Full Text] [Related]
20. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
